Abivax SA Sponsored ADR (ABVX) – What Are Investment Firms Thinking About This Stock?

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned an average recommendation of “Moderate Buy” from the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $155.00.

ABVX has been the topic of a number of analyst reports. Wedbush lowered their price objective on shares of Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. Truist Financial cut their price objective on shares of Abivax from $155.00 to $151.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Guggenheim restated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Tuesday, October 20th. Piper Sandler restated an “overweight” rating on shares of Abivax in a research note on Wednesday, October 21st. Finally, Barclays reaffirmed an “overweight” rating and issued a $148.00 target price on shares of Abivax in a report on Tuesday, September 22nd.

Abivax Stock Performance

Abivax stock traded down $2.62 during mid-day trading on Tuesday, reaching $87.58. 698,793 shares of the company were exchanged, compared to its average volume of 853,150. The firm’s 50-day simple moving average is $94.85 and its two-hundred day simple moving average is $112.53. Abivax has a twelve month low of $69.81 and a twelve month high of $148.83. The firm has a market cap of $7.67 billion, a PE ratio of -14.45 and a beta of 1.36.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The firm had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.80 million. As a group, equities research analysts anticipate that Abivax will post -4.14 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ABVX. Two Seas Capital LP purchased a new stake in Abivax during the third quarter worth about $66,996,000. Seven Fleet Capital Management LP grew its position in Abivax by 218.9% during the first quarter. Seven Fleet Capital Management LP now owns 43,052 shares of the company’s stock worth $4,794,000 after buying an additional 29,553 shares during the period. Vilga Financial Planning LLC purchased a new position in Abivax in the third quarter valued at about $2,178,000. Militia Capital Management LLC acquired a new stake in shares of Abivax during the 1st quarter valued at approximately $1,893,000. Finally, Brummer Multi Strategy AB lifted its position in shares of Abivax by 56.0% during the 1st quarter. Brummer Multi Strategy AB now owns 22,428 shares of the company’s stock valued at $2,497,000 after acquiring an additional 8,053 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

About Abivax

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.